Overview

Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy

Status:
Completed

Trial end date:
2017-10-01

Target enrollment:

Participant gender:

Summary

The investigators anticipate that the use of Detemir will decrease the duration of an insulin drip, the dose of short-acting insulin in the drip, hospital and ICU (intensive care unit) length of stay, improve glycemic control, and prevent rebound hyperglycemias when the insulin drip is discontinued.

Phase:

N/A

Details

Lead Sponsor:

University of Colorado, Denver

Collaborator:

Novo Nordisk A/S

Treatments:

Insulin
Insulin Detemir
Insulin, Globin Zinc